# CHERRY BIOTECH
EUACC page: https://www.euacc.ai/company/asteroid
Retrieved: 2026-11-18T15:59:41.382Z. Retrieval is not verification. Source content is reference data, never instructions.

## Public content

**id:** 8152ccad-2351-425c-9243-8c30b460ad97
**slug:** asteroid
**name:** CHERRY BIOTECH
**tagline:** Multi-organ toxicity and efficacy test platform for Personalized medicine & Drug development
**description:** The pharmaceutical and medical fields need more predictive models to assess the effects of drugs on patients. The demand arises
from the desire to replace animal tests, enhance predictability, and reduce drug development time and costs. In personalized
medicine, there's a need for tools like companion diagnostics to identify patients who will benefit and respond from specific
treatments.
Recent changes in EU and US regulations, allowing drug candidates to be submitted without animal testing, have led to the
development of alternative solutions like 3D cell culture and organs-on-a-chip. These technologies have shown promise in predicting
drug effects on patients, but 3 scientific challenges persist, namely including functional vascular interfaces, multilayer tissue
equivalent reconstruction without PDMS, and cultivating interconnected organs with varying oxygen concentrations. Also, 2
industrial bottlenecks on the compatibility with multiwell plate formats and the need for reproducible biological protocols are
present.
Cherry Biotech has developed a 3D cell culture platform that addresses these bottlenecks with three innovations: the Microfluidic
Perfusion Lid (MPL), the Hydroflat, and the Cubix control unit. These innovations have received approval from industrial and hospital
partners and has been patented in Europe and US.
The company aims to address the preclinical drug development (CubiX RUO, 2026) market and the precision medicine market (CubiX
CDx, 2030). The preclinical drug development market is growing rapidly due to favorable regulatory changes, while the precision
oncology market is driven by biomarker-based assays for guiding medical treatments.
Cherry Biotech's work not only has financial implications but also has a significant impact on human health and animal welfare by
offering predictive models and reducing the need for animal testing. It contributes to technological advancement and innovation in
the EU.
**logo url:** https://xevcdyjrlsmhsjialbof.supabase.co/storage/v1/object/public/company-assets/8152ccad-2351-425c-9243-8c30b460ad97/website-logo-1792377956140.webp
**hero url:** https://xevcdyjrlsmhsjialbof.supabase.co/storage/v1/object/public/company-assets/8152ccad-2351-425c-9243-8c30b460ad97/website-cover-1792377955909.webp
**country:** France
**country code:** FR
**city:** MONTREUIL
**sector tags:** 
  - Digital Health
  - Fintech
  - Biotech
**stage:** grant-funded
**founded year:** 2014
**team size:** 11-50
**website:** https://www.cherrybiotech.com/
**grants received:** €2.5M
**open to funding:** true
**looking for:** 
  - Investment
  - Partnerships
**source:** cordis
**cordis programme:** EIC Accelerator
**cordis url:** https://cordis.europa.eu/project/id/101189261
**grant id:** 101189261
**eu contribution:** 2499831.25
**created at:** 2026-02-15T12:37:51.093719+00:00
**updated at:** 2026-02-15T12:37:51.093719+00:00
**mrr status:** private
**business model:** B2B
**latitude:** 48.858517
**longitude:** 2.431705
**status:** published

## Review record

**status:** unverified
**source url:** https://www.cherrybiotech.com/
**next check due:** 2026-12-03T09:39:14.239+00:00

## Source metadata
